Clinical Trial Design: Statistical Options/Challenges Panel Discussion

First International Summit on Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Sep

Today In Oncology

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Biomarker Guides Treatment Sequencing Predicts Outcomes in BRAF-Mutated Metastatic Melanoma

High-Dose Vitamin D3 Does Not Improve PFS in Metastatic Colorectal Cancer

Additional Safety Analysis of DESTINY-Breast05: What Did It Show?

FDA Approves Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia

FDA Approves Rusfertide for Erythrocytosis in Adults With Polycythemia Vera